Iovance Biotherapeutics I... (IOVA)
3.50
0.25 (7.69%)
At close: Apr 02, 2025, 11:24 AM
Iovance Biotherapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
| Revenue | 164.07M | 1.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 124M | 10.76M | 21.14M | 13.98M | 8.71M | 8.12M | 956K | 952K | 978K | 999K | 9.34M | 4.66M | 6.48M | 19.3M | n/a | n/a | n/a |
| Gross Profit | 40.08M | -9.57M | -21.14M | -13.98M | -8.71M | -8.12M | -956K | -952K | -978K | -999K | -9.34M | -4.66M | -6.48M | -19.3M | n/a | n/a | n/a |
| Operating Income | -395.28M | -460.56M | -398.88M | -342.7M | -261.94M | -206.87M | -128.26M | -92.88M | -53.64M | -27.86M | -12.04M | -22.64M | -8.13M | -21.22M | -815.41K | -15.77K | -57.14K |
| Interest Income | 20.27M | 13.04M | 2.98M | 451K | 2.36M | 9.32M | n/a | 813K | 745K | 200K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -375M | -447.52M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M | -27.66M | -12.03M | -25.38M | -3.31M | -25.69M | -1.61M | -15.77K | -57.14K |
| Net Income | -372.18M | -444.04M | -389.92M | -327.82M | -257.23M | -187.07M | -123.58M | -92.06M | -52.89M | -27.66M | -12.03M | -25.38M | -3.31M | -25.69M | -1.61M | -15.77K | -57.14K |
| Selling & General & Admin | 153.02M | 106.92M | 104.1M | 83.66M | 60.21M | 40.85M | 28.43M | 21.26M | 25.6M | 12.39M | 9.34M | 4.66M | 6.48M | 19.3M | n/a | 14.44K | 25.56K |
| Research & Development | 282.34M | 344.08M | 294.78M | 259.04M | 201.73M | 166.02M | 99.83M | 71.61M | 28.04M | 15.47M | 2.7M | 1.33M | 1.66M | 1.76M | n/a | n/a | n/a |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 16.66M | n/a | 19.3M | 815.41K | 15.77K | 57.14K |
| Operating Expenses | 435.35M | 450.99M | 398.88M | 342.7M | 261.94M | 206.87M | 128.26M | 92.88M | 53.64M | 27.86M | 12.04M | 22.64M | 8.13M | 21.06M | 815.41K | 15.77K | 57.14K |
| Interest Expense | n/a | n/a | 2.98M | n/a | n/a | n/a | n/a | n/a | n/a | 200K | 5.66K | 444.73K | 2.42M | 151.51K | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | 79.22M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 559.35M | 461.75M | 398.88M | 342.7M | 261.94M | 206.87M | 128.26M | 92.88M | 53.64M | 27.86M | 12.04M | 22.64M | 8.13M | 21.06M | 815.41K | 15.77K | 57.14K |
| Income Tax | -2.83M | -3.48M | -5.97M | -14.43M | -2.36M | -10.48M | 4.68M | -952K | -978K | -999K | n/a | 444.73K | 2.42M | 4.64M | 792.58K | n/a | n/a |
| Shares Outstanding (Basic) | 289.88M | 235.13M | 159.26M | 153.41M | 138.3M | 124.34M | 97.28M | 65.24M | 55.27M | 44.41M | 24.99M | 9.76M | 798.53K | 759.24K | 652.46K | 381K | 1.21M |
| Shares Outstanding (Diluted) | 289.88M | 235.13M | 159.26M | 153.41M | 138.3M | 124.34M | 97.28M | 65.24M | 55.27M | 44.41M | 24.99M | 9.76M | 798.53K | 759.24K | 652.46K | 381K | 1.21M |
| EPS (Basic) | -1.28 | -1.89 | -2.45 | -2.14 | -1.86 | -1.5 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -2.6 | -4.14 | -33.84 | -2.46 | -0.04 | -0.05 |
| EPS (Diluted) | -1.28 | -1.89 | -2.45 | -2.14 | -1.86 | -1.5 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -2.6 | -4.14 | -33.84 | -2.46 | -0.04 | -0.05 |
| EBITDA | -395.28M | -427.43M | -374.76M | -328.27M | -250.87M | -189.43M | -122.62M | -91.11M | -51.92M | -26.66M | -11.95M | -24.93M | 508.81K | -20.54M | -1.55M | -14.44K | -55.81K |
| EBIT | -395.28M | -460.56M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M | -27.66M | -12.03M | -24.94M | 502.6K | -20.54M | -1.61M | -15.77K | -57.14K |
| Depreciation & Amortization | n/a | 33.13M | 21.14M | 13.98M | 8.71M | 8.12M | 956K | 952K | 978K | 999K | 88.22K | 7.09K | 6.21K | 2.7K | 58.6K | 1.33K | 1.33K |